Navigation Links
Topical Spray Helped Men With Premature Ejaculation

Study found they could delay orgasm six times longer than before

MONDAY, April 6 (HealthDay News) -- A new spray enabled men with premature ejaculation to delay their orgasm six times longer than before, according to a study that included 300 European men.

The men, with clinically diagnosed premature ejaculation, were randomly selected to receive a placebo spray with no active ingredients (100 men) or the PSD502 spray, which contains 7.5 milligrams of lidocaine and 2.5 mg of prilocaine (200 men).

During the three-month study, the men used either the placebo or the PSD502 spray five minutes before intercourse. The men and their partners then used a stopwatch to record the time from vaginal penetration to ejaculation. The men were instructed to abstain from sexual activity or masturbation for 24 hours before each recorded episode of intercourse.

The men who used the PSD502 spray (treatment group) delayed their orgasm from an average of 0.6 minutes to 3.8 minutes, compared to just over 1 minute for those who used the placebo spray. That means the PSD502 spray helped men last 6.3 times longer than normal, compared to 1.7 times longer than normal for those who used the placebo, the study authors said.

The study found that after three months of treatment:

  • 90 percent of the men in the treatment group were able to delay ejaculation for more than 1 minute following vaginal penetration, compared with 54 percent of those in the placebo group.
  • 74 percent of men in the treatment group were able to last 2 minutes before ejaculation, compared with 22 percent of those in the placebo group.
  • 62 percent of men in the treatment group said their orgasms were "good" or "very good" after three months, compared with 20 percent before the start of the study. For men in the placebo group, the figures were 19 percent at the end of the study and 21 percent before the start of the study.
  • More patients and partners in the treatment group reported improvements in perceived control, personal distress, satisfaction with sexual intercourse, and interpersonal problems.

The most common problems noted in the study were loss of erection and a burning sensation in the vagina.

The study findings were published in the April issue of the journal BJU International.

"Premature ejaculation can be a very distressing condition for men and can cause distress, frustration and make them avoid sexual intimacy," lead researcher Professor W. Wallace Dinsmore, of the Royal Victoria Hospital in Belfast, U.K., said in a news release.

"Our study shows that when the PSD502 spray was applied to the man's penis five minutes before intercourse it improved both sexual performance and sexual satisfaction, which are key factors in treating premature ejaculation."

More information

The U.S. National Library of Medicine has more about premature ejaculation.

-- Robert Preidt

SOURCE: BJU International, news release, April 6, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
2. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
3. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
4. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
5. Topical treatment for age spots, from Harvard Womens Health Watch
6. Summit VetPharm Introduces New Feline Topicals Vectra(TM) for Cats & Kittens and Vectra(TM) for Cats
7. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
8. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
9. Topical Cream Treats Precancerous Lesions of Vulva
10. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
11. Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution)
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: